The Diagnostic Accuracy of Galectin-9 for Diagnosis of Endometriosis in Comparison with Laparoscopy

Jarollahi, Sahar; Chaichian, Shahla; Jarollahi, Ali; Hajmohammadi, Roya; Mashayekhi, Reza; Shahmohammadi, Fereshteh; Eslamivaghar, Mohammad; Ghasemi, Ziba

doi:10.18502/jri.v23i4.10812

The Diagnostic Accuracy of Galectin-9 for Diagnosis of Endometriosis in Comparison with Laparoscopy

Authors

Sahar Jarollahi ¹

Shahla Chaichian ²

Ali Jarollahi ³

Roya Hajmohammadi ³

Reza Mashayekhi ³

Fereshteh Shahmohammadi ¹

Mohammad Eslamivaghar ¹

Ziba Ghasemi ¹

¹ Islamic Azad University of Medical Sciences, Tehran, Iran

² Islamic Azad University of Medical Sciences, Tehran, Iran; Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran

³ Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran

10.18502/jri.v23i4.10812

Abstract

Background: Endometriosis is a common devastating gynecological disease with severe complications. Researches on noninvasive diagnostic tests with acceptable accuracy are still ongoing. The purpose of the present study was to evaluate the diagnostic value of serum Galectin-9 (Gal-9) level in comparison with laparoscopic results in endometriosis patients. Methods: Sixty-one patients, referred to Booali, Rasool-e-Akram, and Pars Hospitals affiliated to Islamic Azad University of Medical Sciences, were recruited. Patients laparoscopically diagnosed with endometriosis were assigned to the case (n=32) and who diagnosed with other diseases were assigned to the control group (n=29). In general, 56 patients (30 in case and 26 in control group) completed the study. The serum level of Galectin-9 was measured using ELISA method before laparoscopy and was compared between the groups. Next, categorical variables were compared using Chi square and quantitative variables using independent samples t-test or Mann-Whitney U test. The Gal-9 cut-off was calculated using the Youden’s index and ROC curve; then, sensitivity, specificity, positive and negative predictive value, and positive and negative likelihood ratio of Gal-9 were reported. The p<0.05 were considered statistically significant. Results: Mean serum level of Galectin-9 was 669.3±416.50 pg/ml in the case group and 265.42±492.30 pg/ml in the control group (p=0.001). Considering a cut-off value of 138 pg/ml, Galectin-9 had a sensitivity of 100% and specificity of 88.46% for diagnosis of endometriosis (p<0.001). Conclusion: Galectin-9 measurement is helpful in diagnosis of endometriosis. Future studies are recommended for investigating the generalizability of these results.

Keywords

Biomarkers

diagnostic tests

Endometriosis

Galectin

Laparascopy

Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34-41.

Riazi H, Tehranian N, Ziaei S, Mohammadi E, Hajizadeh E, Montazeri A. Clinical diagnosis of pelvic endometriosis: a scoping review. BMC Womens Health. 2015;15:39.

Vitale SG, La Rosa VL, Rapisarda AMC, Laganà AS. Endometriosis and infertility: the impact on quality of life and mental health. J Endometr Pelvic Pain Dis. 2017;9(2):112-5.

Mehdizadeh Kashi A, Moradi Y, Chaichian S, Najmi Z, Mansori K, Salehin F, et al. Application of the world health organization quality of life instrument, short form (WHOQOL-BREF) to patients with endometriosis. Obstet Gynecol Sci. 2018;61(5):598-604.

Mehedintu C, Plotogea M, Ionescu S, Antonovici M. Endometriosis still a challenge. J Med Life. 2014;7(3):349-57.

Zhang S, Gong TT, Wang HY, Zhao YH, Wu QJ. Global, regional, and national endometriosis trends from 1990 to 2017. Ann N Y Acad Sci. 2021;1484(1):90-101.

Malvezzi H, Marengo EB, Podgaec S, de Azevedo Piccinato C. Endometriosis: current challenges in modeling a multifactorial disease of unknown etiology. J Transl Med. 2020;18(1):311.

Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. F1000Res. 2019;8:F1000 Faculty Rev-529.

Chaichian S. Surgical management of endo-metriosis. Ann Bariatric Surg. 2013;2(4):100-10.

Dana PM, Taghavipour M, Mirzaei H, Yousefi B, Moazzami B, Chaichian S, et al. Circular RNA as a potential diagnostic and/or therapeutic target for endometriosis. Biomark Med. 2020;14(13):1277-87.

Taghavipour M, Sadoughi F, Mirzaei H, Yousefi B, Moazzami B, Chaichian S, et al. Apoptotic functions of microRNAs in pathogenesis, diagnosis, and treatment of endometriosis. Cell Biosci. 2020;10:12.

Kamili NA, Arthur CM, Gerner‐Smidt C, Tafesse E, Blenda A, Dias‐Baruffi M, et al. Key regulators of galectin–glycan interactions. Proteomics. 2016;16(24):3111-25.

Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP, et al. Galectin-3: one molecule for an alphabet of diseases, from A to Z. Int J Mol Sci. 2018;19(2):379.

Yilmaz H, Celik H, Ozdemir O, Kalkan D, Namuslu M, Abusoglu S, et al. Serum galectin-3 levels in women with PCOS. J Endocrinol Invest. 2014;37(2):181-7.

Hisrich BV, Young RB, Sansone AM, Bowens Z, Green LJ, Lessey BA, et al. Role of human galectins in inflammation and cancers associated with endometriosis. Biomolecules. 2020;10(2):230.

Menkhorst EM, Gamage T, Cuman C, Kaitu'u-Lino T, Tong S, Dimitriadis E. Galectin-7 acts as an adhesion molecule during implantation and increased expression is associated with miscarriage. Placenta. 2014;35(3):195-201.

Noël JC, Chapron C, Borghese B, Fayt I, Anaf V. Galectin-3 is overexpressed in various forms of endometriosis. Appl Immunohistochem Mol Morphol. 2011;19(3):253-7.

de Mattos RM, Machado DE, Perini JA, Alessandra-Perini J, da Costa NdOM, de Oliveira AFdR, et al. Galectin-3 plays an important role in endometriosis development and is a target to endometriosis treatment. Mol Cell Endocrinol. 2019;486:1-10.

Chen HL, Liao F, Lin TN, Liu FT. Galectins and neuroinflammation. In: Yu R, Schengrund, CL, editors. Glycobiology of the nervous system. New York: Springer; 2014. p. 517-42.

Yang H, Yin J, Ficarrotta K, Hsu S, Zhang W, Cheng C. Aberrant expression and hormonal regulation of Galectin-3 in endometriosis women with infertility. J Endocrinol Invest. 2016;39(7):785-91.

Bastón JI, Barañao RI, Ricci AG, Bilotas MA, Olivares CN, Singla JJ, et al. Targeting galectin‐1‐induced angiogenesis mitigates the severity of endometriosis. J Pathol. 2014;234(3):329-37.

Popovici RM, Krause MS, Germeyer A, Strowitzki T, von Wolff M. Galectin-9: a new endometrial epithelial marker for the mid-and late-secretory and decidual phases in humans. J Clin Endocrinol Metab. 2005;90(11):6170-6.

Shimizu Y, Kabir-Salmani M, Azadbakht M, Sugihara K, Sakai K, Iwashita M. Expression and localization of galectin-9 in the human uterodome. Endocr J. 2008;55(5):879-87.

Brubel R, Bokor A, Pohl A, Schilli GK, Szereday L, Bacher-Szamuel R, et al. Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. Fertil Steril. 2017;108(6):1016-25.e2.

Canis M, Donnez JG, Guzick DS, Halme JK, Rock JA, Schenken RS, et al. Revised american society for reproductive medicine classification of endometriosis: 1996. Fertil Steril. 1997;67(5):817-21.

Flores I, Waelkens E, D'Hooghe T. Noninvasive diagnosis of endometriosis: review of current peripheral blood and endometrial biomarkers. Best Pract Res Clin Obstet Gynaecol. 2018;50:72-83.

Nisenblat V, Bossuyt PM, Shaikh R, Farquhar C, Jordan V, Scheffers CS, et al. Blood biomarkers for the non‐invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016;2016(5): CD012179.

Rokhgireh S, Mehdizadeh Kashi A, Chaichian S, Delbandi AA, Allahqoli L, Ahmadi-Pishkuhi M, et al. The diagnostic accuracy of combined enolase/Cr, CA125, and CA19-9 in the detection of endometriosis. Biomed Res Int. 2020;2020:5208279.

Hirsch M, Duffy JM, Deguara CS, Davis CJ, Khan KS. Diagnostic accuracy of Cancer Antigen 125 (CA125) for endometriosis in symptomatic women: a multicenter study. Eur J Obstet Gynecol Reprod Biol. 2017;210:102-7.

Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS, International collaboration to harmonise outcomes and measures for endometriosis. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta‐analysis. BJOG. 2016;123(11):1761-8.

Moar P, Tandon R. Galectin-9 as a biomarker of disease severity. Cell Immunol. 2021;361:104287.

Brooks AK, Lawson MA, Rytych JL, Yu KC, Janda TM, Steelman AJ, et al. Immunomodulatory factors galectin-9 and interferon-gamma synergize to induce expression of rate-limiting enzymes of the kynurenine pathway in the mouse hippocampus. Front Immunol. 2016;7:422.

Meggyes M, Szereday L, Bohonyi N, Koppan M, Szegedi S, Marics-Kutas A, et al. Different expression pattern of TIM-3 and Galectin-9 molecules by peripheral and peritoneal lymphocytes in women with and without endometriosis. Int Mol Sci. 2020;21(7):2343.

Ahn SH, Monsanto SP, Miller C, Singh SS, Thomas R, Tayade C. Pathophysiology and immune dysfunction in endometriosis. Biomed Res Int. 2015;2015:795976.

Králíčková M, Vetvicka V. Immunological aspects of endometriosis: a review. Ann Transl Med. 2015;3(11):153.

Kor E, Mostafavi SRS, Mazhin ZA, Dadkhah A, Kor A, Arvanagh SH, et al. Relationship between the severity of endometriosis symptoms (dyspareunia, dysmenorrhea and chronic pelvic pain) and the spread of the disease on ultrasound. BMC Res Notes. 2020;13(1):546.